Compare Citius Pharmaceuticals Inc (CTXR) vs Marathon Petroleum Corp (MPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Marathon Petroleum Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Marathon Petroleum Corp trades at $300.65 (market cap $88.57B). The key difference: Marathon Petroleum Corp is far larger — about 6049.9× Citius Pharmaceuticals Inc's market cap, and Marathon Petroleum Corp pays a 1.29% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | MPC | |
|---|---|---|
Market Cap | $14.64M | $88.57B |
Sector | Health | Energy |
52-Week High | $1.82 | $303.40 |
52-Week Low | $0.53 | $158.59 |
Enterprise Value | $10.86M | $120.75B |
Dividend Yield | — | 1.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Marathon Petroleum (MPC) trades at $296.88, up 4.63% today and near its 52-week high. The stock shows strong momentum with bullish moving averages and a consensus analyst rating of Buy (75.76%). Recent earnings beat expectations in Q4 2025 and Q1 2026, though revenue has declined from $177.5B in 2022 to $132.7B in 2025. The company maintains solid profitability with a 3.42% net margin and 27.92% ROE, supported by a dividend payment of $1.00 scheduled for June 2026.
MPC's outlook is positive due to elevated refining margins and analyst optimism, but risks include volatile oil prices, legal challenges over AI pricing allegations, and declining revenue trends. The stock trades above the consensus price target of $292.70, suggesting limited near-term upside despite strong institutional support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →
